RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Corey A., Oronsky, Bryan T., Caroen, Scott Z., Scicinski, Jan J., Degesys, Aiste, Kim, Michelle M., Oronsky, Arnold L., Lybeck, Harry, Cabrales, Pedro, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Brzezniak, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: March, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/
https://www.ncbi.nlm.nih.gov/pubmed/27065849
http://dx.doi.org/10.1159/000444631
_version_ 1782425533138599936
author Carter, Corey A.
Oronsky, Bryan T.
Caroen, Scott Z.
Scicinski, Jan J.
Degesys, Aiste
Kim, Michelle M.
Oronsky, Arnold L.
Lybeck, Harry
Cabrales, Pedro
Oronsky, Neil
Reid, Tony
Roswarski, Joseph
Brzezniak, Christina
author_facet Carter, Corey A.
Oronsky, Bryan T.
Caroen, Scott Z.
Scicinski, Jan J.
Degesys, Aiste
Kim, Michelle M.
Oronsky, Arnold L.
Lybeck, Harry
Cabrales, Pedro
Oronsky, Neil
Reid, Tony
Roswarski, Joseph
Brzezniak, Christina
author_sort Carter, Corey A.
collection PubMed
description RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.
format Online
Article
Text
id pubmed-4821137
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-48211372016-04-08 RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets Carter, Corey A. Oronsky, Bryan T. Caroen, Scott Z. Scicinski, Jan J. Degesys, Aiste Kim, Michelle M. Oronsky, Arnold L. Lybeck, Harry Cabrales, Pedro Oronsky, Neil Reid, Tony Roswarski, Joseph Brzezniak, Christina Case Rep Oncol Published online: March, 2016 RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization. S. Karger AG 2016-03-11 /pmc/articles/PMC4821137/ /pubmed/27065849 http://dx.doi.org/10.1159/000444631 Text en Copyright © 2016 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Published online: March, 2016
Carter, Corey A.
Oronsky, Bryan T.
Caroen, Scott Z.
Scicinski, Jan J.
Degesys, Aiste
Kim, Michelle M.
Oronsky, Arnold L.
Lybeck, Harry
Cabrales, Pedro
Oronsky, Neil
Reid, Tony
Roswarski, Joseph
Brzezniak, Christina
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
title RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
title_full RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
title_fullStr RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
title_full_unstemmed RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
title_short RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
title_sort rrx-001 in refractory small-cell lung carcinoma: a case report of a partial response after a third reintroduction of platinum doublets
topic Published online: March, 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/
https://www.ncbi.nlm.nih.gov/pubmed/27065849
http://dx.doi.org/10.1159/000444631
work_keys_str_mv AT cartercoreya rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT oronskybryant rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT caroenscottz rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT scicinskijanj rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT degesysaiste rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT kimmichellem rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT oronskyarnoldl rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT lybeckharry rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT cabralespedro rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT oronskyneil rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT reidtony rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT roswarskijoseph rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets
AT brzezniakchristina rrx001inrefractorysmallcelllungcarcinomaacasereportofapartialresponseafterathirdreintroductionofplatinumdoublets

Ejemplares similares